Gentian violet induces wtp53 transactivation in cancer cells

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1084-1090

  Garufi, Alessia ^a   D'Orazi, Valerio ^b   Arbiser, Jack L ^c   D'Orazi, Gabriella ^a,d  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cancer therapy; DNA binding; Gene expression; Gentian violet; NADPH oxidase 1; p53 transcriptional activity

Indexed keywords

ANTINEOPLASTIC AGENT; CRYSTAL VIOLET; DNA BINDING PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOX1 PROTEIN, HUMAN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOPICAL ANTIINFECTIVE AGENT; TP53 PROTEIN, HUMAN;

APOPTOSIS; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; HUMAN; METABOLISM; NEOPLASMS; PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENTIAN VIOLET; HCT116 CELLS; HISTONES; HUMANS; NADPH OXIDASE; NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894479569     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2304     Document Type: Article

References (35)

1. Vousden KH and Lane DP: P53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007.
2. Schuler M and Green DR: Transcription, apoptosis and p53: catch-22. Trends Genet 2: 182-187, 2005.
3. Vazquez A, Bond EE, Levine AJ and Bond LG: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Disc 7: 979-984, 2008.
4. Muller PAJ and Vousden KH: P53 mutations in cancer. Nat Cell Biol 15: 2-8, 2013.
5. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D and D'Orazi G: HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer 8: 1-14, 2009.
6. Puca R, Nardinocchi L, Starace G, Rechavi G, Sacchi A, Givol D and D'Orazi G: Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Rad Biol Med 48: 1338-1346, 2010.
7. Arbiser JL, Petros J, Kiafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS and Lambeth JD: Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 99: 715-720, 2002.
8. Block K and Gorin Y: Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer 12: 627-637, 2012.
9. Docampo R and Moreno SN: The metabolism and mode of action of gentian violet. Drug Metab Rev 22: 161-178, 1990.
10. Maley AM and Arbiser JL: Gentian Violet: A 19th century drug re-emerges in the 21st century. Exp Dermatol: Oct 7, 2013. doi: 10.1111/exd.12257.
11. Perry BN, Govindarajan B, Bhandarkar SS, Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont D, Losken A, Williams J, Brown LF, Tan X, Yancopoulos GD and Arbiser JL: Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126: 2316-2322, 2006.
12. Lapidoth M, Ben-Amitai D, Bhandarakar S, Fried J and Arbiser JL: Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 60: 350-351, 2009.
13. Arbiser JL, Bips M, Seidler A, Bonner MY and Kovach C: Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol 67: e81-e33, 2012.
14. Ingraham MA: The bacteriostatic action of Gentian Violet and dependence on the oxidation-reduction potential. J Bacteriol 26: 573-598, 1933.
15. Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, Perry BN, Parhar R, Mackelfresh J, Sohn A, Stouffs M, Knaus U, Yancopoulos G, Reiss Y, Benest AV, Augustin HG and Arbiser JL: Fulvene-5 potently inhibits NAPDH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 119: 2359-2365, 2009.
16. Zhang X, Zheng Y, Fried LE, Du Y, Montano SJ, Sohn A, Lefkove B, Holmgren L, Arbiser JL, Holmgren A and Lu J: Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Rad Biol Med 50: 811-820, 2011.
17. Newick K, Cunniff B, Preston K, Held P, Arbiser JL, Pass H, Mossmann B, Shukla A and Heintz N: Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PloS One 7: e39404, 2012.
18. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D and D'Orazi G: Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 68: 3707-3714, 2008.
19. Biroccio A, Del Bufalo D, Ricca A, D'Angelo C, D'Orazi G, Sacchi A, Soddu S and Zupi G: Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Ther 6: 1064-1072, 1999.
20. D'Avenia P, Porrello A, Berardo M, D'Angelo M, Soddu S, Arcangeli G, Sacchi A and D'Orazi G: TP53-gene transfer induces hupersensitivity to low-dose of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett 231: 102-112, 2006.
21. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737, 1999.
22. Chen C and Hokayama H: High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752, 1987.
23. Di Stefano V, Soddu S, Sacchi A and D'Orazi G: HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic DNA damage. Oncogene 24: 5431-5442, 2005.
24. Podhorecka M, Skladanowski A and Bozko P: H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucl Acids ID: 920161, 2010.
25. Arbiser JL: Gentian violet is safe. J Am Acad Derm 61: 359, 2009.
26. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
27. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA and Arnold RS: Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62: 200-207, 2005.
28. Laurent E, McCoy JW, Macinz RA, Liu W, Cheng G, Robine S, Papkoff J and Lambeth JD: Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. Int J Cancer 123: 100-107, 2008.
29. Chiera F, Meccia E, Degan P, Aquilina G, Pietraforte D, Minetti M, Lambeth JD and Bignami M: Overexpression of human NOX1 complex induces genome instability in mammalian cells. Free Rad Biol Med 44: 332-342, 2008.
30. Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873, 2009.
31. Selivanova G and Wiman KG: Reactivation of mutant p53: molecular mechanisms and therapeutical potential. Oncogene 26: 2243-2254, 2007.
32. Oren M: Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031-36034, 1999.
33. Meek DW: Mechanisms of switching on p53: a role for covalent modification? Oncogene 18: 7666-7675, 1999.
34. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824-1827, 2000.
35. Hecker D, Page G, Lohrum M, Weiland S and Scheidtmann KH: Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 12: 953-961, 1996.